FreeTheAI

Kyowa Kirin Reports Positive Real-World Study Data for Cancer Drug Mogamulizumab

BullishMedium impact
4151¥2,222.50 0.61%

Kyowa Kirin Co., Ltd. (TSE:4151) released final German real-world study results for its therapy mogamulizumab in 109 patients treated for mycosis fungoides and Sézary syndrome. The study showed a median time to next treatment of 14.9 months, a best overall response rate of 62.4%, and a median progression-free survival of 20.2 months.

The findings offer clinical confirmation of the drug's effectiveness and safety outside of formal clinical trials. Results varied by condition, with a median time to next treatment of 20.2 months for Sézary syndrome and 12.0 months for mycosis fungoides. Additionally, patients experiencing mogamulizumab-associated rash achieved a 95.7% disease control rate, while general safety matched earlier pivotal trial observations.

Future drivers for the therapy could include official label expansions, updated clinical guidelines, or broader reimbursement agreements that support expanded usage. Kyowa Kirin stock closed up 0.61% at 2,222 JPY.

Key points

  • Kyowa Kirin Co., Ltd. reported final real-world study data from 109 patients treated with mogamulizumab.
  • Patients achieved a median time to next treatment of 14.9 months and a best overall response rate of 62.4%.
  • The median progression-free survival reached 20.2 months across the study population.
  • Patients experiencing rash associated with mogamulizumab achieved a 95.7% disease control rate.
  • Kyowa Kirin Co., Ltd. (TSE:4151) stock rose 0.61% to 2,222 JPY following the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the key results for mogamulizumab in the real-world study?

In 109 patients, mogamulizumab demonstrated a median time to next treatment of 14.9 months, a best overall response rate of 62.4%, and median progression-free survival of 20.2 months.

What was the disease control rate for patients with mogamulizumab-associated rash?

Patients experiencing mogamulizumab-associated rash achieved a disease control rate of 95.7%.

How did results differ between Sézary syndrome and mycosis fungoides?

The median time to next treatment was 20.2 months for Sézary syndrome patients compared to 12.0 months for mycosis fungoides patients.